GlycoMimetics Announces National Cancer Institute Phase 2/3 Study of Uproleselan Did Not Meet Primary Endpoint

GLYC 10.29.2024

Full Press ReleaseSEC FilingsOur GLYC Tweets

About Gravity Analytica

Recent News

  • 11.06.2024 - GlycoMimetics Announces New Uproleselan Clinical Data Will Be Presented at ASH Annual Meeting
  • 10.29.2024 - Corporate Update Call
  • 10.29.2024 - GlycoMimetics Enters Into Acquisition Agreement With Crescent Biopharma

Recent Filings

  • 01.13.2025 - 8-K Current report
  • 01.13.2025 - EX-99.1 EX-99.1
  • 01.13.2025 - DEFA14A Additional definitive proxy soliciting materials and Rule 14(a)(12) material
PDF Version

ROCKVILLE, Md.--(BUSINESS WIRE)--Oct. 29, 2024--GlycoMimetics, Inc.(Nasdaq: GLYC), a late clinical-stage biotechnology company discovering and developing glycobiology-based therapies for cancers and inflammatory diseases, today announced the Phase 2 analysis of the adaptive Phase 2/3 study of uproleselan being conducted by theNational Cancer Institute(NCI) and theAlliance for Clinical Trialsin Oncology in adults with newly diagnosed acute myeloid leukemia (AML) who are 60 years or older and fit for intensive chemotherapy. This study did not show a statistically significant improvement in event free survival (EFS) for patients receiving uproleselan in combination with 7+3 chemotherapy versus chemotherapy alone.

GlycoMimeticsis coordinating with the Alliance for transfer of full trial data for additional analysis, including subgroup analysis to evaluate if there are efficacy signals in any patient population that may merit further study in future clinical trials. Top-line results from NCI/Alliance trial are expected to be presented by the NCI at a future medical conference.

AboutGlycoMimetics, Inc.

GlycoMimeticsis a late clinical-stage biotechnology company discovering and developing glycobiology-based therapies for cancers, including AML, and for inflammatory diseases. The company’s scientific approach is based on an understanding of the role that carbohydrates play in cell recognition. Its specialized chemistry platform can be used to discover small molecule drugs, known as glycomimetics, that alter carbohydrate-mediated recognition in diverse disease states, including cancers and inflammation. The company’s goal is to develop transformative therapies for diseases with high unmet medical need.GlycoMimeticsis headquartered inRockville, MDin theBioHealth Capital Region. Learn more atwww.glycomimetics.com.

Forward-Looking Statements

This press release contains forward-looking statements. These forward-looking statements may include, but are not limited to, statements regarding the conduct of, and timing for analysis and presentation of data from, clinical trials; and potential development and regulatory activities. Actual results may differ materially from those described in these forward-looking statements. For a further description of the risks associated with these statements, as well as other risks facingGlycoMimetics, please see the risk factors described in the company’s Annual Report on Form 10-K filed with theU.S. Securities and Exchange Commission(SEC) onMarch 27, 2024, the company’s Quarterly Reports on Form 10-Q filed with theSEConMay 9, 2024andAugust 8, 2024, and other filingsGlycoMimeticsmakes with theSECfrom time to time. Forward-looking statements speak only as of the date of this release, andGlycoMimeticsundertakes no obligation to update or revise these statements, except as may be required by law.

View source version onbusinesswire.com:https://www.businesswire.com/news/home/20241029684934/en/

Investor:Argot PartnersLeo Vartorella212-600-1902Glycomimetics@argotpartners.com

Source:GlycoMimetics, Inc.

Please be aware that the following content has been generated by an AI system and may contain errors, inconsistencies, or outdated information. It is provided as-is without any warranties or guarantees of accuracy. We strongly recommend using this content as a starting point for further research and consultation with relevant experts or authorities. We disclaim any liability for damages or losses resulting from the use or reliance on this content.Please note that this is a beta version of the Gravity Analytica LLC’s AI Service which isstill undergoing final testing before its official release. Theplatform, its software and all content found on it are provided on an“as is” and “as available” basis. Gravity Analytica LLC does not give any warranties,whether express or implied, as to the suitability or usability of thisservice, webpage, or its software or any of its content.Should you encounter any bugs, glitches, lack of functionality orother problems on the website, please let us know immediately so wecan rectify these accordingly. Your help in this regard is greatlyappreciated! You can write to us at this addressteam@gravityanalytica.com